In 2022, the FDA approved an accelerated TMS protocol for depression known as the Stanford Neuromodulation Therapy (SNT) protocol, previously called the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol. This approach was developed specifically to improve the results received with TMS. It consists of five days of treatment, with 10 sessions of intermittent theta burst stimulation each day, the use of greater pulse dose of stimulation, and more targeted application of stimulation using individual MRIs paired with precision tracking equipment for coil placement.
Clinical studies have demonstrated rapid improvements in depressive symptoms among those who received this protocol. Results of limited studies show that around 90% of the patients with treatment-resistant depression met remission criteria following the accelerated TMS treatments, and testing demonstrated no negative cognitive side effects. These results are based on small sample sizes, but are about twice as good as conventional rTMS treatments!
The Stanford protocol is generally considered the foundation of modern accelerated TMS protocols. Variations and development of accelerated protocols incorporate details of clinical practice, current best practices, cost effectiveness adjustments, and other considerations. As with most medical procedures, there is variability in the accelerated protocol from provider to provider.